Andrew J Roebuck1, Wendie N Marks1, Max C Liu1, Nimra B Tahir1, Nadine K Zabder1, Terrance P Snutch2, John G Howland3. 1. Department of Physiology, University of Saskatchewan, GD30.7, Health Sciences Building, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada. 2. Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Colombia, Vancouver, BC, Canada. 3. Department of Physiology, University of Saskatchewan, GD30.7, Health Sciences Building, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada. john.howland@usask.ca.
Abstract
RATIONALE: Currently available antipsychotics are unsatisfactory given their side effects and limited efficacy for the cognitive symptoms of schizophrenia. Many currently available drugs, such as haloperidol, are T-type calcium channel antagonists in addition to their well-established antagonism of dopamine D2 receptors. Thus, preclinical research into the effects of T-type calcium channel antagonists/blockers in behavioral assays related to schizophrenia may inform novel therapeutic strategies. OBJECTIVES: We explored the effects of a recently developed highly selective T-type calcium channel antagonist, Z944 (2.5, 5.0, 10.0 mg/kg), on the MK-801 (0.15 mg/kg) model of acute psychosis. METHODS: To examine the effects of Z944 on behaviors relevant to schizophrenia, we tested touchscreen-based paired associates learning given its relevance to the cognitive symptoms of the disorder and locomotor activity given its relevance to the positive symptoms. RESULTS: Acute treatment with Z944 failed to reverse the visuospatial associative memory impairments caused by MK-801 in paired associates learning. The highest dose of drug (10.0 mg/kg) given alone produced subtle impairments on paired associates learning. In contrast, Z944 (5.0 mg/kg) blocked the expected increase in locomotion following MK-801 treatment in a locomotor assay. CONCLUSIONS: These experiments provide support that Z944 may reduce behaviors relevant to positive symptoms of schizophrenia, although additional study of its effects on cognition is required. These findings and other research suggest T-type calcium channel antagonists may be an alternative to currently available antipsychotics with less serious side effects.
RATIONALE: Currently available antipsychotics are unsatisfactory given their side effects and limited efficacy for the cognitive symptoms of schizophrenia. Many currently available drugs, such as haloperidol, are T-type calcium channel antagonists in addition to their well-established antagonism of dopamine D2 receptors. Thus, preclinical research into the effects of T-type calcium channel antagonists/blockers in behavioral assays related to schizophrenia may inform novel therapeutic strategies. OBJECTIVES: We explored the effects of a recently developed highly selective T-type calcium channel antagonist, Z944 (2.5, 5.0, 10.0 mg/kg), on the MK-801 (0.15 mg/kg) model of acute psychosis. METHODS: To examine the effects of Z944 on behaviors relevant to schizophrenia, we tested touchscreen-based paired associates learning given its relevance to the cognitive symptoms of the disorder and locomotor activity given its relevance to the positive symptoms. RESULTS: Acute treatment with Z944 failed to reverse the visuospatial associative memory impairments caused by MK-801 in paired associates learning. The highest dose of drug (10.0 mg/kg) given alone produced subtle impairments on paired associates learning. In contrast, Z944 (5.0 mg/kg) blocked the expected increase in locomotion following MK-801 treatment in a locomotor assay. CONCLUSIONS: These experiments provide support that Z944 may reduce behaviors relevant to positive symptoms of schizophrenia, although additional study of its effects on cognition is required. These findings and other research suggest T-type calcium channel antagonists may be an alternative to currently available antipsychotics with less serious side effects.
Authors: Michael F Egan; Xin Zhao; Andrew Smith; Matthew D Troyer; Victor N Uebele; Valerii Pidkorytov; Kevin Cox; Michael Murphy; Duane Snavely; Christopher Lines; David Michelson Journal: Hum Psychopharmacol Date: 2013-03 Impact factor: 1.672
Authors: Donald C Goff; Peter Falkai; W Wolfgang Fleischhacker; Ragy R Girgis; Rene M Kahn; Hiroyuki Uchida; Jingping Zhao; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2017-05-05 Impact factor: 18.112
Authors: Daniela Cadinu; Ben Grayson; Giovanni Podda; Michael K Harte; Nazanin Doostdar; Joanna C Neill Journal: Neuropharmacology Date: 2017-11-28 Impact factor: 5.250